Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund
Headed into the biggest oncology research and development confab of the year, an investment firm partnered with one of the nation’s premier cancer institutions is looking at a hefty second batch of capital to support ...
Headed into the biggest oncology research and development confab of the year, an investment firm partnered with one of the nation’s premier cancer institutions is looking at a hefty second batch of capital to support ...
